RxDoctor Payments Data

Mark Franz, DO

Physical Medicine & Rehabilitation · Dunbar, PANPI 1427101807

Payments from drug & device makers

$2,267in general payments, 2019–2025

Across 158 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$732
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$217
  • Novo Nordisk$213
  • Biohaven Pharmaceutical Holding Company Ltd.$199
  • Lilly USA, LLC$183
  • GSK$161
  • plus $562 from 11 others

What the payments were for

  • Food & beverage$2,267100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,267 in reported general payments places this provider in the 85th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

See all physical medicine & rehabilitation providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$142,869
Medicare patients
103
Services billed
2,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$39,454
JardianceEmpagliflozin42$38,670
TrulicityDulaglutide29$28,186
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,641
OzempicSemaglutide11$16,250
EntrestoSacubitril/Valsartan16$16,246
JanuviaSitagliptin Phosphate26$15,791
TradjentaLinagliptin15$10,814
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$9,541
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$6,410
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen279$4,529
PaxlovidNirmatrelvir/Ritonavir12$4,287
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen284$4,046
Insulin Lispro Kwikpen U-100Insulin Lispro16$3,976
VascepaIcosapent Ethyl11$3,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$138$43,74255 claims
Lilly USA, LLCTrulicity$183$28,18629 claims
GSKTrelegy Ellipta$161$16,64123 claims
Novo NordiskOzempic$213$16,25011 claims
NovartisEntresto$36$16,24616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

Other physical medicine & rehabilitation in Dunbar

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →